Establishing a reasonable price for an orphan drug

BACKGROUND: This paper addresses the question of what a reasonable price for an orphan drug is. The research proposes a way to adjust an established payer/HTA body incremental cost-effectiveness threshold (CET) to take account of differences in patient populations and costs of research and developme...

Descripción completa

Detalles Bibliográficos
Autores principales: Berdud, Mikel, Drummond, Michael, Towse, Adrian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472708/
https://www.ncbi.nlm.nih.gov/pubmed/32908456
http://dx.doi.org/10.1186/s12962-020-00223-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472708/
https://www.ncbi.nlm.nih.gov/pubmed/32908456
http://dx.doi.org/10.1186/s12962-020-00223-x

Ejemplares similares